MXCT PE Ratio & Valuation,Is MXCT Overvalued

MXCT Relative Valuation

MXCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MXCT is overvalued; if below, it's undervalued.

Historical Valuation

MaxCyte Inc (MXCT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -16.56. The fair price of MaxCyte Inc (MXCT) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：1.49

Fair

-5.84

-3.13

EV/EBITDA

MaxCyte Inc. (MXCT) has a current EV/EBITDA of -3.13. The 5-year average EV/EBITDA is -16.86. The thresholds are as follows: Strongly Undervalued below -66.24, Undervalued between -66.24 and -41.55, Fairly Valued between 7.82 and -41.55, Overvalued between 7.82 and 32.51, and Strongly Overvalued above 32.51. The current Forward EV/EBITDA of -3.13 falls within the Historic Trend Line -Fairly Valued range.

-2.21

EV/EBIT

MaxCyte Inc. (MXCT) has a current EV/EBIT of -2.21. The 5-year average EV/EBIT is -11.65. The thresholds are as follows: Strongly Undervalued below -42.75, Undervalued between -42.75 and -27.20, Fairly Valued between 3.91 and -27.20, Overvalued between 3.91 and 19.46, and Strongly Overvalued above 19.46. The current Forward EV/EBIT of -2.21 falls within the Historic Trend Line -Fairly Valued range.

4.40

MaxCyte Inc. (MXCT) has a current PS of 4.40. The 5-year average PS is 12.44. The thresholds are as follows: Strongly Undervalued below -3.21, Undervalued between -3.21 and 4.62, Fairly Valued between 20.27 and 4.62, Overvalued between 20.27 and 28.10, and Strongly Overvalued above 28.10. The current Forward PS of 4.40 falls within the Undervalued range.

0.00

P/OCF

MaxCyte Inc. (MXCT) has a current P/OCF of 0.00. The 5-year average P/OCF is -22.64. The thresholds are as follows: Strongly Undervalued below -109.93, Undervalued between -109.93 and -66.28, Fairly Valued between 21.00 and -66.28, Overvalued between 21.00 and 64.64, and Strongly Overvalued above 64.64. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-7.96

P/FCF

MaxCyte Inc. (MXCT) has a current P/FCF of -7.96. The 5-year average P/FCF is -23.96. The thresholds are as follows: Strongly Undervalued below -95.60, Undervalued between -95.60 and -59.78, Fairly Valued between 11.87 and -59.78, Overvalued between 11.87 and 47.69, and Strongly Overvalued above 47.69. The current Forward P/FCF of -7.96 falls within the Historic Trend Line -Fairly Valued range.

MaxCyte Inc (MXCT) has a current Price-to-Book (P/B) ratio of 0.89. Compared to its 3-year average P/B ratio of 1.71 , the current P/B ratio is approximately -48.24% higher. Relative to its 5-year average P/B ratio of 2.58, the current P/B ratio is about -65.60% higher. MaxCyte Inc (MXCT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -9.45%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -7.31% , the current FCF yield is about -100.00% lower.

0.89

P/B

Median3y

1.71

Median5y

2.58

-25.43

FCF Yield

Median3y

-9.45

Median5y

-7.31

Competitors Valuation Multiple

The average P/S ratio for MXCT's competitors is 0.00, providing a benchmark for relative valuation. MaxCyte Inc Corp (MXCT) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -16.35%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of MXCT decreased by 64.18% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -141.56 to -181.81.

The secondary factor is the Revenue Growth, contributed -16.35%to the performance.

Overall, the performance of MXCT in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-16.35%

8.16M → 6.83M

Revenue Growth

28.43%

-141.56 → -181.81

Margin Expansion

-76.26%

-14.70 → -3.49

P/E Change

-64.18%

4.16 → 1.49

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is MaxCyte Inc (MXCT) currently overvalued or undervalued?

What is MaxCyte Inc (MXCT) fair value?

MXCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of MaxCyte Inc (MXCT) is between NaN to NaN according to relative valuation methord.

How does MXCT's valuation metrics compare to the industry average?

What is the current P/B ratio for MaxCyte Inc (MXCT) as of Dec 16 2025?

As of Dec 16 2025, MaxCyte Inc (MXCT) has a P/B ratio of 0.89. This indicates that the market values MXCT at 0.89 times its book value.

What is the current FCF Yield for MaxCyte Inc (MXCT) as of Dec 16 2025?

As of Dec 16 2025, MaxCyte Inc (MXCT) has a FCF Yield of 0.00%. This means that for every dollar of MaxCyte Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for MaxCyte Inc (MXCT) as of Dec 16 2025?

As of Dec 16 2025, MaxCyte Inc (MXCT) has a Forward P/E ratio of -5.84. This means the market is willing to pay $-5.84 for every dollar of MaxCyte Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for MaxCyte Inc (MXCT) as of Dec 16 2025?

As of Dec 16 2025, MaxCyte Inc (MXCT) has a Forward P/S ratio of 0.00. This means the market is valuing MXCT at $0.00 for every dollar of expected revenue over the next 12 months.

MXCT Valuation